1 – 19 of 19
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
New Inhibitors in the Ageing Population : A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
- 2021
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
- 2018
-
Mark
The role of the laboratory in diagnosis and management of inhibitory antibodies in haemophilia
(
- Contribution to journal › Article
- 2016
-
Mark
Current view and outcome of ITI therapy : A change over time?
(
- Contribution to journal › Article
- 2015
-
Mark
Strategies for reducing inhibitor formation in severe haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Genetic risk factors for inhibitors in haemophilia A
(
- Contribution to journal › Scientific review
-
Mark
Non-genetic risk factors and their influence on the management of patients in the clinic
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B - a systematic literature review
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
- 2008
-
Mark
Value added: increasing the power to assess treatment outcome in joint haemorrhages
(
- Contribution to journal › Article
-
Mark
From theory to practice: Applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors
(
- Contribution to journal › Scientific review
- 2007
-
Mark
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
- 2006
-
Mark
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
(
- Contribution to journal › Article
-
Mark
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
-
Mark
Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
(
- Contribution to journal › Article
- 2001
-
Mark
The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients
(
- Contribution to journal › Article
-
Mark
Symposium in memory of Professor Inga Marie Nilsson
(
- Contribution to journal › Published meeting abstract